380.47
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
Will United Therapeutics Corporation benefit from rate cutsQuarterly Market Summary & Reliable Price Breakout Alerts - khodrobank.com
Does United Therapeutics Corporation have declining or rising EPSJuly 2025 Closing Moves & Weekly Market Pulse Updates - khodrobank.com
United Therapeutics stock price target raised to $560 from $415 at UBS - Investing.com
Using Bollinger Bands to evaluate United Therapeutics Corporation2025 Dividend Review & Safe Capital Investment Plans - Newser
What’s next for United Therapeutics Corporation stock price2025 Growth vs Value & Daily Momentum Trading Reports - Newser
How hedge fund analytics apply to United Therapeutics Corporation stock2025 Bull vs Bear & Verified Entry Point Detection - Newser
United Therapeutics Corporation (NASDAQ:UTHR) Surges 38% Yet Its Low P/E Is No Reason For Excitement - simplywall.st
Detecting support and resistance levels for United Therapeutics Corporation2025 Technical Overview & Accurate Intraday Trade Tips - Newser
Mannkind Corporation shares rise 1.22% premarket after United Therapeutics' drug Tyvaso shows significant lung function improvement. - AInvest
Is United Therapeutics Corporation forming a bottoming baseJuly 2025 Pullbacks & Real-Time Chart Pattern Alerts - Newser
Does United Therapeutics Corporation show high probability of rebound2025 Big Picture & High Conviction Buy Zone Picks - Newser
Is United Therapeutics Corporation stock entering bullish territoryDividend Hike & Daily Entry Point Trade Alerts - Newser
Can machine learning forecast United Therapeutics Corporation recovery2025 Valuation Update & Long Hold Capital Preservation Tips - Newser
How to build a dashboard for United Therapeutics Corporation stockWall Street Watch & Daily Stock Trend Watchlist - Newser
Is United Therapeutics Corporation a turnaround storyMarket Risk Report & Expert Verified Movement Alerts - khodrobank.com
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results - Stocktwits
United Therapeutics Corporation’s volatility index tracking explainedPortfolio Growth Summary & Intraday High Probability Setup Alerts - Newser
United Therapeutics: On the Rise? - timothysykes.com
Why United Just Catapulted 39%, Pulling Two Rivals With It - Investor's Business Daily
United Therapeutics Shares Soar: Will Momentum Last? - StocksToTrade
Moving Averages: Is United Therapeutics Corporation stock influenced by commodity prices2025 Pullback Review & High Accuracy Swing Trade Signals - khodrobank.com
United Therapeutics Shares Surge on Strong Lung-Drug Trial Results - citybiz
United Therapeutics surges as Tyvaso succeeds in IPF trial: should you invest? - CryptoRank
United Therapeutics stock jumps as Jefferies raises price target on IPF study - Investing.com
United Therapeutics stock hits all-time high on successful drug trial - The Business Journals
UBS Lifts United Therapeutics’ Price Target to Drive Optimism - StocksToTrade
UBS Lifts United Therapeutics Price Target Amid Positive Study Results - timothysykes.com
Is United Therapeutics Corporation meeting your algorithmic filter criteriaWeekly Trend Report & Free Growth Oriented Trading Recommendations - Newser
United’s Tyvaso surprise in IPF potentially opens $4B market - BioWorld MedTech
Why Is United Therapeutics Stock Rallying On Tuesday?United Therapeutics (NASDAQ:UTHR) - Benzinga
United Therapeutics stock hits all-time high at $419.63 - Investing.com
United Therapeutics shares surge as lung disease drug meets main study goal - TradingView
PepsiCo, United Therapeutics Lead Market Cap Stock Movers on Tuesday - Investing.com
United Therapeutics shares surge after Tyvaso IPF trial hits key goal - MSN
United Therapeutics’ Stunning Leap: What’s Behind It? - StocksToTrade
United Therapeutics' TETON-2 Trial Shows Tyvaso Improves Lung Function In IPF Patients - Nasdaq
PepsiCo, Ionis Pharma, United Therapeutics - TradingView
United Therapeutics Corporation announces Teton-2 pivotal study of Tyvaso meets primary endpoint for the treatment of idiopathic pulmonary fibrosis - MarketScreener
United Therapeutics posts Tyvaso trial win (UTHR:NASDAQ) - Seeking Alpha
United Therapeutics Announces Positive TETON-2 Study Results - TipRanks
95.6mL Lung Function Improvement: United Therapeutics' Tyvaso Achieves Breakthrough in IPF Treatment Trial - Stock Titan
Published on: 2025-09-01 20:26:35 - Newser
Published on: 2025-09-01 19:48:53 - Newser
What is United Therapeutics Corporation’s valuation compared to sectorPortfolio Return Report & Weekly Market Pulse Alerts - khodrobank.com
Measuring United Therapeutics Corporation’s beta against major indicesJuly 2025 Review & Risk Controlled Swing Trade Alerts - Newser
United Therapeutics Corporation Rebound Backed by Sentiment Shift getLinesFromResByArray error: size == 0 - 강소기업뉴스
Using flow based indicators on United Therapeutics CorporationQuarterly Growth Report & Fast Gain Swing Alerts - Newser
United Therapeutics Corporation Recovery Gathers Momentum on Chart Signals getLinesFromResByArray error: size == 0 - kangso.co.kr
Will United Therapeutics Corporation rebound enough to break evenWeekly Stock Report & Low Volatility Stock Recommendations - Newser
Tick level data insight on United Therapeutics Corporation volatilityBear Alert & Momentum Based Trading Ideas - Newser
Momentum divergence signals in United Therapeutics Corporation chart2025 Earnings Impact & Precise Swing Trade Alerts - Newser
Published on: 2025-08-31 13:32:31 - Newser
Candlestick signals on United Therapeutics Corporation stock todayDividend Hike & Safe Capital Growth Tips - Newser
Does United Therapeutics Corporation qualify in momentum factor screeningTrade Analysis Report & Community Consensus Trade Signals - Newser
What MACD signals say about United Therapeutics CorporationShare Buyback & AI Powered Market Entry Ideas - Newser
Published on: 2025-08-30 23:59:10 - Newser
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):